- Published at
- by gurufocus.com
neutral
neutral
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD”‘1/L1 therapySEE